ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Defitelio®:MEDA Pharmaceuticals Switzerland GmbH
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
B01AX01 - DefibrotideATC-DDD Version 2016. Source: WHO
B - Blood and Blood Forming Organs
 
B01 - Antithrombotic Agents
 
B01A - Antithrombotic Agents
 
B01AX - Other Antithrombotic Agents
 

The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.

B01AX01 - Defibrotide
DoseRoute of administrationNote
 P 
2025 ©ywesee GmbH
Settings | Help | Login | Contact | Home